Serving all people by providing personalized health and wellness through exemplary care, education and research.
Explore health content from A to Z.
I need information about...
Baylor Research Institute (BRI) conducts clinical trials involving islet cell transplantation and investigational therapies for type 1 and 2 diabetes. This research determines the effectiveness of investigational medications/insulin regimens to achieve desired glucose control in both type 1 and 2 diabetes, while testing new technologies and methods to deliver insulin. Continued research of diabetes allows Baylor to address the basic pathophysiology as well as replacement therapies for diabetes.
BRI’s laboratory is researching a technique that involves ultrasound-targeted microbubble destruction (UTMD) to deliver drugs or genes to specific tissues. Drugs or genes are attached to gas-filled microbubbles, which are circulated through the intravascular space and mechanically destroyed within the target organ by ultrasound. Our most recent data demonstrates the ability to increase insulin secretion by using UTMD to deliver genes, inducing pancreatic cells to produce and secrete insulin, reversing type 1 diabetes in rats.
More on Research Studies at Baylor
Copyright © 2016 Baylor Scott & White Health. All Rights Reserved. |
3500 Gaston Ave., Dallas, TX 75246-2017 | 1.800.4BAYLOR